Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
Sight Sciences, Inc. officer James Rodberg gave notice of a proposed sale of 7,208 common shares, for an aggregate market value of $63,813.86, with an approximate sale date of October 2, 2026. The notice identifies restricted stock vesting from the issuer on September 30, 2026; it says the sale includes an amount needed to cover tax from settlement of a vested equity award. Rodberg reported selling 6,902 shares on July 2, 2026, for $36,959.51. Jennifer Ruchti signed as an authorized representative of Fidelity Brokerage Services LLC and attorney-in-fact for Rodberg.
Sight Sciences, Inc. (SGHT) reports a Rule 144 notice for Paul Badawi’s proposed sale of 29,653 common shares, with an aggregate market value of $268,332.96 and an approximate sale date of October 1, 2026. The listed acquisition was restricted stock vesting on September 30, 2026; the remarks say the sale includes an amount necessary to cover a tax obligation from settling a vested equity award distribution. Fidelity Brokerage Services LLC is listed as broker, and Joshua Schmitt signed as its duly authorized representative and attorney-in-fact for Badawi.
Sight Sciences, Inc. (SGHT) reports a proposed sale by David Y. Badawi, identified as an officer and director, of 7,797 common shares, with an approximate sale date of October 1, 2026, through Fidelity Brokerage Services LLC. The notice lists an aggregate market value of $70,555.84. Badawi acquired 7,797 shares through restricted stock vesting on September 30, 2026. The notice says the sale includes an amount necessary to cover the tax obligation resulting from settlement of the vested equity award distribution.
Jeremy Hayden, a former officer of Sight Sciences, Inc. (SGHT), gave notice of a proposed sale of 2,746 common shares, with an aggregate market value of $24,768.92 and an approximate sale date of October 1, 2026. The notice lists Fidelity Brokerage Services LLC as the broker and NASDAQ as the exchange. It also lists 55,087,990 common shares outstanding and reports prior sales, including 48,000 shares for $395,880.00 on August 14, 2026.
Sight Sciences, Inc. former officer Jeremy Hayden reported a proposed sale of 22,254 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $208,051.65 and an approximate sale date of September 30, 2026. The notice separately lists common-share sales by Hayden from July 6 through September 4, 2026.
Sight Sciences, Inc. (SGHT) is the issuer for a Rule 144 notice filed for the account of former officer Jeremy B. Hayden covering planned sales of common stock. The notice lists 12,219 shares of common stock to be sold, associated with restricted stock vesting on August 31, 2026, held in an account at Fidelity Brokerage Services LLC.
The filing also lists several prior sales of Sight Sciences common stock by Jeremy Hayden during the past three months, each with its own date, share amount, and aggregate sale price. The notice is signed on September 4, 2026, by Jessica Spraker as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Jeremy Hayden.
Sight Sciences, Inc. (SGHT) is the issuer for a planned sale of common stock reported under Rule 144 for the account of former officer Jeremy B. Hayden. A brokerage account at Fidelity Brokerage Services LLC filed notice to sell up to 13,253 shares of SGHT common stock, with an indicated value of $109,974.72. The securities relate to restricted stock vesting on 08/31/2026, received from the issuer as compensation. The filer notes that the sale includes an amount necessary to cover a tax obligation arising from settlement of a vested equity award.
In the prior three months, Jeremy Hayden reported several open-market sales of SGHT common stock, including 12,733 shares on 07/06/2026 for $70,132.10 and 48,000 shares on 08/14/2026 for $395,880.00, along with additional transactions on 08/11/2026, 08/12/2026, 08/13/2026, and 08/17/2026.
Sight Sciences, Inc. (SGHT) reported that its Chief Legal Officer, the reporting person in this Form 4, received an equity compensation award. The officer was granted 181,818 restricted stock units (RSUs) of common stock for no cash consideration, increasing the officer’s directly held common stock-related position to 181,818 shares on an as-converted basis.
The RSUs were granted under Sight Sciences’ 2021 Incentive Award PlanAugust 10, 2027 and continuing through August 10, 2030, subject to the officer’s continued service with Sight Sciences on each vesting date. Each RSU represents a contingent right to receive one share of Sight Sciences common stock.
Sight Sciences, Inc. (SGHT) reported that Kashif Rashid, serving as Chief Legal Officer, filed an initial Form 3 as an officer of the company. The filing lists no reportable transactions or equity holdings and includes a Power of Attorney authorizing Form 3-related actions.
Sight Sciences, trading under symbol SGHT, has a filing stating that shareholder Jeremy Hayden plans to sell up to 12,014 shares of common stock through Fidelity Brokerage Services LLC on or after August 17, 2026 on NASDAQ, with an indicated aggregate market value of $97,841.48.
The disclosure also lists prior common stock sales by Hayden during July and August 2026, and notes that some shares derive from restricted stock vesting granted as compensation on January 1, 2024 and June 30, 2026.